News & Resources

Overview

Webcast ImageWebcast
Q1 2016 Orexigen Therapeutics, Inc. Earnings Conference Call (Live)
05/04/16 at 2:00 p.m. PT
Q1 2016 Orexigen Therapeutics, Inc. Earnings Conference Call
Wednesday, May 4, 2016 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.45
Change (%) Stock is Down 0.02 (4.26%)
Volume1,573,660
Apr 29, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
04/28/16Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity FederationPrinter Friendly Version
04/25/16Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New EmployeesPrinter Friendly Version
04/20/16Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016Printer Friendly Version
03/15/16Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with ValeantPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.